1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Biomarkers in Amyotrophic Lateral Sclerosis

Biomarkers in Amyotrophic Lateral Sclerosis

  • August 2014
  • -
  • Insight Pharma Reports

Overview

Biomarkers in Amyotrophic Lateral Sclerosis is focused on the biomarker identification and development in patients with Amyotrophic Lateral Sclerosis (ALS). As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the ALS space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Parkinson’s Disease, Biomarkers in Amyotrophic Lateral Sclerosis captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:
Dr. Merit Ester Cudkowicz, Chief of Neurology at Massachusetts General Hospital
Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers
Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured by an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications. To add even more to the robustness of this report, Insight Pharma Reports also garnered a table of clinical trial information and pipeline data related to ALS. This table features companies, targets, clinical phases, and brief target/product descriptions.

Table Of Contents

Biomarkers in Amyotrophic Lateral Sclerosis
Table of Contents
Executive Summary
CHAPTER 1: The Focus of this Report
CHAPTER 2: Biomarkers and Their Clinical Utility
What are Biomarkers?
Advantages of Biomarkers
Clinical Endpoints vs. Surrogate Endpoints
Advantages of Biomarkers as Surrogate Endpoints
Disadvantages to Biomarkers as Surrogate Endpoints
How are Biomarkers Validated?
CHAPTER 3: Biomarkers in Neurodegenerative Disorders
CHAPTER 4: Amyotrophic Lateral Sclerosis
What is Amyotrophic Lateral Sclerosis?
Genetic Markers Identifying ALS
SOD1
C9orf72
Fused in Sarcoma (FUS)
TDP-43
Potential Biomarker Candidates for ALS
TDP-43
pNF-H
Cystatin C
Other Biomarkers
Interview with Dr. Merit Ester Cudkowicz
Research Background
ALS Research
Research Advantages and Challenges
ALS outlook
CHAPTER 5: Biomarkers for Diagnostics
Atlantic Biomarkers: Research Background
Mass-Spectrometry Assays for Biomarkers
Impact on Healthcare
Interview with Dr. Andreas Jeromin
Company Background
Neurobiomarker Research
Mass Spectrometry-Based Assays
CHAPTER 6:Survey Results
CHAPTER 7: Clinical Trials and Pipeline Information for Amyotrophic Lateral Sclerosis*
References
About Cambridge Healthtech Institute


Tables and Figures

Figure 2.1: Growth of Interest in Biomarkers
Figure 2.2: Biomarker Presence in Diagnostic Development vs. Therapeutic Development
Figure 3.1: Comparison of Disease Categories
Figure 3.2: Growth of Interest in Biomarkers for Neurology
Figure 3.3: Growth of Interest in Biomarkers for Amyotrophic Lateral Sclerosis
Figure 6.1: How Would You Categorize Your Organization?
Figure 6.2: Which Neurodegenerative Condition are You Currently Studying?
Figure 6.3: Which Targets for Huntington's Disease (HD) are You Currently Studying?*
Figure 6.4: What is the Clinical Status of Your Target(s) for HD?*
Figure 6.5: When Do You Expect Your Targets for HD to Enter Clinical Trials?
Figure 6.6: When Do You Expect Your Target to be an Available Therapeutic for HD?
Figure 6.7: Which Targets for Amyotrophic Lateral Sclerosis (ALS) are You Currently Studying?*
Figure 6.8: What is the Clinical Status of Your Target(s) for ALS?*
Figure 6.9: When Do You Expect Your Targets for ALS to Enter Into Clinical Trials?
Figure 6.10: When Do You Expect Your Target to be an Available Therapeutic for ALS?
Figure 6.11: Which Targets for Multiple Sclerosis (MS) are You Currently Studying?*
Figure 6.12: What is the Clinical Status of Your Target(s) for MS?*
Figure 6.13: When Do You Expect Your Targets for MS to Enter Into Clinical Trials?
Figure 6.14: When Do You Expect Your Target for MS to be an Available Therapeutic?
Figure 6.15: Which Signatures for Alzheimer's Disease (AD) are You Currently Studying?*
Figure 6.16: What is the Clinical Status of Your Target(s) for AD?*
Figure 6.17: When Do You Expect Your Targets for AD to Enter Into Clinical Trials?
Figure 6.18: When Do You Expect Your Target to be an Available Therapeutic for AD?
Figure 6.19: Which Signatures for Parkinson's Disease (PD) are You Currently Studying?* 37
Figure 6.20: What is the Clinical Status of Your Target(s) for PD?*
Figure 6.21: When Do You Expect Your Targets for PD to Enter Into Clinical Trials?
Figure 6.22: When Do You Expect Your Targets for PD to be an Available Therapeutic?
Figure 6.23: How Would You Describe Your Line of Research?
Figure 6.24: With Respect to Neurodiagnostics, Which Diagnostic Tools are You Developing for Biomarker Signatures?*
Figure 6.25: With Respect to Neurodiagnostics, What are Challenges You Have Encountered with Your Diagnostic Development?*
Figure 6.26: With Respect to Biomarker Development, What Tools are You Using to Identify Biomarker Signatures?*
Figure 6.27: With Respect to Biomarker Development, What are Challenges You Have Encountered with Your Therapeutic Discovery/Development?*
Figure 6.28: With Respect to Biomarker Therapeutics, What Tools are You Using to Identify Biomarker Signatures?*
Figure 6.29: With Respect to Biomarker Therapeutics, What are Challenges You Have Encountered with Your Therapeutic Discovery/Development?*
Figure 6.30: Which Imaging Techniques do You Feel are the Most Beneficial for Studying the Effects of Neurodegenerative Diseases?*
Figure 6.31: Which Therapeutics do You Feel will be the Most Beneficial for Neurodegenerative Diseases?*

Table 2.1: Clinical Applications of Biomarkers as Surrogate Endpoints

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.